ReviewFrontiers in psychiatry2023
Review in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Psychotherapy and inhibitory control: Insights from fMRI research.Psychiatry and clinical neurosciences · 2026Pooled it
- Association between androgenetic alopecia and psychological well-being: a systematic review and meta-analysis.Frontiers in psychiatry · 2025Pooled it
- Ginsenoside Rh1 Modulates GABAergic Inhibitory Homeostasis and Mitochondrial Quality Control During Lead (Pb)-Associated Neuronal Dysfunction.Molecules (Basel, Switzerland) · 2026Article
- PIWI-piRNA Axis in Epilepsy: Bridging Epigenetic Regulation, Neuroinflammation, and Neuronal Excitability.Molecular neurobiology · 2026Review
- The impact of pregestational stress on neurodevelopment: Implications for autism spectrum disorder and attention-deficit/hyperactivity disorder.The Journal of physiology · 2026Review
- The Gut Microbiome in Early Ontogeny: Implications for Brain and Immune System Development.Journal of developmental biology · 2026Review
- Autophagic Pathway on GABARAP Involved in GABANeurochemical research · 2026Review
- GABA-Producing Bacteria as Potential Psychobiotics in Gut-Brain Axis Regulation.International journal of molecular sciences · 2026Review
- Metformin reverses oxandrolone-induced anxiety-like behavior and amygdalar neurochemical dysregulation in male rats.Psychopharmacology · 2026Article
- Central neurons encode interleukin-1β signals and mediate stress-induced inflammation.The Journal of experimental medicine · 2026Article
- Neonatal seizures and GABAergic drugs: Scylla and Charybdis?Epilepsia open · 2026Review
- Early life shifts in cortical inhibitory-excitatory balance underlies sensitive periods and skill development.Frontiers in cellular neuroscience · 2026Article
- Modulatory Effects of Jujuboside A on Amino Acid Neurotransmitter Profiles in Tic Disorder.Brain and behavior · 2025Article
- Neonatal Procedural Pain Disrupts Phosphorylation of KCC2 in the Spinal Cord.Developmental neurobiology · 2025Article
- Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- A novel de novo GABRA2 gene missense variant causing developmental epileptic encephalopathy in a Chinese patient.Annals of clinical and translational neurology · 2025Article
- Gestational Duration and Postnatal Age-Related Changes in Aperiodic and Periodic Parameters in Neonatal and Toddler Electroencephalogram (EEG).Human brain mapping · 2025Article
- Gut microbiota-mediated pain sensitization: mechanisms and therapeutic implications.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- Development of KCC2 therapeutics to treat neurological disorders.Frontiers in molecular neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system. In the mature brain, inhibitory GABAergic signaling is critical in maintaining neuronal homeostasis and vital human behaviors such as cognition, emotion, and motivation. While classically known to inhibit neuronal function under physiological conditions, previous research indicates a paradoxical switch from inhibitory to excitatory GABAergic signaling that is implicated in several neurological disorders. Various mechanisms have been proposed to contribute to the excitatory switch such as chloride ion dyshomeostasis, alterations in inhibitory receptor expression, and modifications in GABAergic synaptic plasticity. Of note, the hypothesized mechanisms underlying excitatory GABAergic signaling are highlighted in a number of neurodevelopmental, substance use, stress, and neurodegenerative disorders. Herein, we present an updated review discussing the presence of excitatory GABAergic signaling in various neurological disorders, and their potential contributions towards disease pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.